MRT-2359
Monte Rosa Therapeutics
['solid tumor', 'mrt-2359']
see gerald gavory present at #aacr23 next week on the development of mrt-2359, our gspt1-directed mgd that is tackling myc-driven solid tumors. 
Monte Rosa Therapeutics is developing next-generation small molecule protein degraders to treat cancer and beyond.